Pfizer (NYSE:PFE) and Astellas reported Phase 3 data showing PADCEV plus Keytruda delivered significant clinical benefits in muscle-invasive bladder cancer. The combination was associated with ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer’s PFE second-quarter 10% revenue growth and adjusted EPS of $0.78 were ahead of consensus expectations. Management maintained full-year revenue guidance of $61 billion-$64 billion and raised ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

--Currently down nine consecutive days; down 11.06% over this period --Longest losing streak since Feb. 25, 2020, when it fell for nine straight trading days --Worst nine-day stretch since the nine ...

Pfizer's third-quarter sales fell 6% year over year to $16.65 billion, beating the consensus of $16.59 billion. The revenue reflected an operational decline of 7%. The operational decrease was ...

Notes landmark agreement with U.S. government: Says voluntary agreement provides greater clarity; reduces uncertainty around tariffs and pricing; allows investment in future innovation and growth.

Dividend stocks can be a great way to generate passive income. Investors must ensure that companies are generating sufficient free cash flow and earnings to cover their dividends, ideally with the ...